Embree Financial Group’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.06M Buy
23,873
+168
+0.7% +$39.2K 0.61% 39
2026
Q1
$5.79M Buy
23,705
+2,312
+11% +$539K 0.68% 33
2025
Q4
$4.43M Buy
21,393
+223
+1% +$44.1K 0.54% 39
2025
Q3
$3.93M Buy
21,170
+177
+0.8% +$30.3K 0.53% 43
2025
Q2
$3.21M Buy
20,993
+265
+1% +$40.7K 0.48% 48
2025
Q1
$3.44M Buy
20,728
+19
+0.1% +$2.97K 0.58% 39
2024
Q4
$2.99M Buy
20,709
+226
+1% +$35K 0.51% 39
2024
Q3
$3.32M Buy
20,483
+77
+0.4% +$12.3K 0.59% 37
2024
Q2
$2.98M Sell
20,406
-132
-0.6% -$19.6K 0.57% 39
2024
Q1
$3.25M Sell
20,538
-791
-4% -$126K 0.64% 36
2023
Q4
$3.34M Buy
+21,329
New +$3.27M 0.7% 31

Other funds holding JNJ

Embree Financial Group's JNJ Position: Q2 2026 in Review

Embree Financial Group increased its Johnson & Johnson (JNJ) stake by 0.71% in Q2 2026, buying an estimated $39.2K and bringing the position to 23,873 shares worth $6.06M. The position accounts for 0.61% of the portfolio, ranked #39.

Embree Financial Group first reported a position in JNJ in Q4 2023 and has held it in 11 quarters since. 2,458 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Embree Financial Group held 23,873 shares of Johnson & Johnson worth $6.06M as of Q2 2026.
  • Embree Financial Group bought 168 Johnson & Johnson shares in Q2 2026, an estimated $39.2K.
  • Johnson & Johnson made up 0.61% of Embree Financial Group's portfolio in Q2 2026, its #39 holding.
  • Embree Financial Group first reported a position in Johnson & Johnson in Q4 2023 and has held it in 11 quarters since.
  • 2,458 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Embree Financial Group's 13F filing for Q2 2026, filed 15 Jul 2026.